{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["105(3)"],"submitter":["Karimi YH"],"pubmed_abstract":["Epcoritamab, a CD3xCD20 bispecific antibody, resulted in deep, durable responses with a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL) in EPCORE<sup>®</sup> NHL-1 (NCT03625037). We report results from a 3-year follow-up. Adults with relapsed/refractory LBCL received epcoritamab until progressive disease or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Median age was 64.0 years, 39% of patients received prior CAR T-cell treatment, and 75% were refractory to ≥ 2 consecutive lines of treatment. As of May 3, 2024 (median follow-up 37.1 months [range, 0.3-45.5]), ORR was 59% and complete response (CR) rate 41% by investigator assessment. Median duration of response was 20.8 months (95% confidence interval [CI], 13.0-32."],"journal":["Annals of hematology"],"pagination":["79"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12868022"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial."],"pmcid":["PMC12868022"],"pubmed_authors":["Karimi YH","Jafarinasabian P","Cunningham D","Clausen MR","Hutchings M","Farooq U","Steele AJ","Phillips T","Soong D","Ghesquieres H","D'Angelo Mansson B","Thieblemont C","Jurczak W","Li Z","Feldman T","Kim WS","Cheah CY","Linton KM","Eskelund CW","Vose JM"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.","description":"Epcoritamab, a CD3xCD20 bispecific antibody, resulted in deep, durable responses with a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL) in EPCORE<sup>®</sup> NHL-1 (NCT03625037). We report results from a 3-year follow-up. Adults with relapsed/refractory LBCL received epcoritamab until progressive disease or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Median age was 64.0 years, 39% of patients received prior CAR T-cell treatment, and 75% were refractory to ≥ 2 consecutive lines of treatment. As of May 3, 2024 (median follow-up 37.1 months [range, 0.3-45.5]), ORR was 59% and complete response (CR) rate 41% by investigator assessment. Median duration of response was 20.8 months (95% confidence interval [CI], 13.0-32.","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T06:32:20.331Z","creation":"2026-06-30T03:21:52.084Z"},"accession":"S-EPMC12868022","cross_references":{"pubmed":["41634395"],"doi":["10.1007/s00277-026-06798-4"]}}